Understanding the why, when and how of gene expression is a complex science. Gene expression profiling gives biomedical researchers a critical tool for developing and testing their hypotheses, helping them form a deeper, more comprehensive picture of cell function and biology. Looking toward the future, emerging applications of RNA-sequencing tools are likely to continue to evolve gene expression profiling – driving the discovery of new disease biomarkers and therapeutic drug targets.
Understanding the why, when and how of gene expression is a complex science. Gene expression profiling gives biomedical researchers a critical tool for developing and testing their hypotheses, helping them form a deeper, more comprehensive picture of cell function and biology. Looking toward the future, emerging applications of RNA-sequencing tools are likely to continue to evolve gene expression profiling – driving the discovery of new disease biomarkers and therapeutic drug targets.
Animal experimentation reduction techniques offer a variety of partial solutions to the enduring controversial issue of animal use in scientific research. In the United States alone, The Humane Society estimates that over 50 million animals are used in experiments annually.
Animal experimentation reduction techniques offer a variety of partial solutions to the enduring controversial issue of animal use in scientific research. In the United States alone, The Humane Society estimates that over 50 million animals are used in experiments annually.
Drug discovery has a translatability problem. The National Institutes of Health (NIH) once famously reported that for every drug that receives FDA approval, another 1,000 fail. In drug development, translatability refers to the basic principle of taking scientific findings from a laboratory setting and successfully translating them as therapeutic patient treatments in a clinical setting. This is sometimes also referred to as the bench-to-bedside process.
Drug discovery has a translatability problem. The National Institutes of Health (NIH) once famously reported that for every drug that receives FDA approval, another 1,000 fail. In drug development, translatability refers to the basic principle of taking scientific findings from a laboratory setting and successfully translating them as therapeutic patient treatments in a clinical setting. This is sometimes also referred to as the bench-to-bedside process.
The FDA Modernization Act strikes out the language referencing animal testing and introduces, in its place, “non-clinical tests” such as those made possible by AI and data modeling. This change has seen a level of bipartisan support rarely witnessed in legislation today, and it is a critical milestone in the history of R&D in that it supports use of simulation and predictive technologies to increase efficiency and candidate success.VeriSIM Life has been ahead of the curve in recognizing these advantages for five years and counting, pioneering the way towards this inevitable industry change by using technology to help clients increase the efficacy of preclinical testing while taking measures towards “de-risking” the process.
The FDA Modernization Act strikes out the language referencing animal testing and introduces, in its place, “non-clinical tests” such as those made possible by AI and data modeling. This change has seen a level of bipartisan support rarely witnessed in legislation today, and it is a critical milestone in the history of R&D in that it supports use of simulation and predictive technologies to increase efficiency and candidate success.VeriSIM Life has been ahead of the curve in recognizing these advantages for five years and counting, pioneering the way towards this inevitable industry change by using technology to help clients increase the efficacy of preclinical testing while taking measures towards “de-risking” the process.